Skip to main content
SpringerLink
Log in

Pain Management in Patients with Hepatic Impairment

  • Chapter
Pain Management and Palliative Care

  • 3144 Accesses

Abstract

Liver disease/cirrhosis affects an estimated 4.5–9.5 % of the overall population (Lim and Kim, Clin Liver Dis 12:733–774, 2008). As a pain management physician, it is very important to treat patients with medications that will not cause exacerbation or progression of their liver pathology.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 109.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 139.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Abbreviations

AUC:

Area under the curve

Cmax:

Maximum concentration

CNS:

Central nervous system

COX:

Cyclooxygenase

CYP:

Cytochrome P450

FDA:

Food and Drug Administration

INR:

International normalized ratio

LFTs:

Liver function tests

NAPQI:

N-Acetyl-p-benzoquinone imine

NMDA:

N-Methyl-d-aspartate

NSAIDs:

Non-steroidal anti-inflammatory drugs

SNRIs:

Serotonin-norepinephrine reuptake inhibitors

References

  1. Lim YS, Kim WR. The global impact of hepatic fibrosis and end-stage liver disease. Clin Liver Dis. 2008;12(4):733–46, vii.

    Article  PubMed  Google Scholar 

  2. Elbekai R, Korashy H, El-Kadi A. The effect of liver cirrhosis on the regulation and expression of drug metabolizing enzymes. Curr Drug Metab. 2004;5(2):157–67.

    Article  CAS  PubMed  Google Scholar 

  3. Verbeeck RK. Pharmacokinetics and dosage adjustment in patients with hepatic dysfunction. Eur J Clin Pharmacol. 2008;64(12):1147–61.

    Article  CAS  PubMed  Google Scholar 

  4. Parlesak A, Schafer C, Schutz T, Bode JC, Bode C. Increased intestinal permeability to macromolecules and endotoxemia in patients with chronic alcohol abuse in different stages of alcohol-induced liver disease. J Hepatol. 2000;32:742–7.

    Article  CAS  PubMed  Google Scholar 

  5. Keshavarzian A, Holmes EW, Patel M, Iber F, Fields JZ, Pethkar S. Leaky gut in alcoholic cirrhosis: a possible mechanism for alcohol-induced liver damage. Am J Gastroenterol. 1999;94:200–7.

    Article  CAS  PubMed  Google Scholar 

  6. Isobe H, Sakai H, Satoh M, Sakamoto S, Nawata H. Delayed gastric emptying in patients with liver cirrhosis. Dig Dis Sci. 1994;39:983–7.

    Article  CAS  PubMed  Google Scholar 

  7. Ishizu H, Shiomi S, Kawamura E, Iwata Y, Nishiguchi S, Kawabe J, Ochi H. Gastric emptying in patients with chronic liver diseases. Ann Nucl Med. 2002;16:177–82.

    Article  PubMed  Google Scholar 

  8. Child CG, Turcotte JG. Surgery and portal hypertension. In: Child CG, editor. The liver and portal hypertension. Philadelphia: Saunders; 1964. p. 50–64.

    Google Scholar 

  9. Pugh RN, Murray-Lyon IM, Dawson JL, et al. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg. 1973;60(8):646–9.

    Article  CAS  PubMed  Google Scholar 

  10. Benson GD. Acetaminophen in chronic liver disease. Clin Pharmacol Ther. 1983;33:95–101.

    Article  CAS  PubMed  Google Scholar 

  11. Zimmerman HJ, Maddrey WC. Acetaminophen (paracetamol) hepatotoxicity with regular intake of alcohol: analysis of instances of therapeutic misadventure. Hepatology. 1995;22:767.

    Article  CAS  PubMed  Google Scholar 

  12. Kuffner EK, Dart RC, Bogdan GM, Hill RE, Casper E, Darton L. Effect of maximal daily doses of acetaminophen on the liver of alcoholic patients: a randomized, double-blinded, placebo-controlled trial. Arch Intern Med. 2001;161:2247.

    Article  CAS  PubMed  Google Scholar 

  13. Chandok N, Watt KDS. Pain management in the cirrhotic patient: the clinical challenge. Mayo Clin Proc. 2010;85(5):451–8.

    Article  PubMed Central  PubMed  Google Scholar 

  14. Rossi S, Assis DN, Awsare M, Brunner M, Skole K, Rai J, Andrel J, Herrine SK, Reddy RK, Navarro VJ. Use of over-the-counter analgesics in patients with chronic liver disease: physicians’ recommendations. Drug Saf. 2008;31(3):261–70.

    Article  PubMed  Google Scholar 

  15. Laffi G, La Villa G, Pinzani M, Marra F, Gentilini P. Arachidonic acid derivatives and renal function in liver cirrhosis. Semin Nephrol. 1997;17(6):530–48.

    CAS  PubMed  Google Scholar 

  16. Castro-Fernandez M, Sanchez-Munoz D, Galan-Jurado MV, Larraona JL, Suarez E, Lamas E, Rodriguez-Hornillo MC, Pabon M. Influence of nonsteroidal antiinflammatory drugs in gastrointestinal bleeding due to gastroduodenal ulcers or erosions in patients with liver cirrhosis. Gastroenterol Hepatol. 2006;29(1):11–4.

    Article  CAS  PubMed  Google Scholar 

  17. Thanacoody HK, Thomas SH. Tricyclic antidepressant poisoning: cardiovascular toxicity. Toxicol Rev. 2005;24(3):205–14.

    Article  CAS  PubMed  Google Scholar 

  18. Cymbalta [package insert]. Indianapolis: Eli Lilly and Company; 2012.

    Google Scholar 

  19. Savella [package insert]. St. Louis: Forest Pharmaceuticals; 2009.

    Google Scholar 

  20. Effexor [package insert]. Philadelphia: Wyeth Pharmaceuticals; 2004.

    Google Scholar 

  21. Pristiq [package insert]. Philadelphia: Wyeth Pharmaceuticals; 2012.

    Google Scholar 

  22. Neurontin [package insert]. New York: Parke-Davis Division of Pfizer; 2012.

    Google Scholar 

  23. yrica [package insert]. New York: Parke-Davis Division of Pfizer; 2012.

    Google Scholar 

  24. Einarsdottir S, Bjornsson E. Pregabalin as a probable cause of acute liver injury. Eur J Gastroenterol Hepatol. 2008;20(10):1049.

    Article  PubMed  Google Scholar 

  25. Topamax [package insert]. Titusville: Janssen Pharmaceuticals; 2009.

    Google Scholar 

  26. Skelaxin [package insert]. Bristol: King Pharmaceutical Inc.; 2007.

    Google Scholar 

  27. See S, Ginzburg R. Skeletal muscle relaxants. Pharmacology. 2008;28(2):207–13.

    CAS  Google Scholar 

  28. Zanaflex [package insert]. Hawthorne: Acorda Therapeutics Inc.; 2010.

    Google Scholar 

  29. Robaxin [package insert]. Smyrna: Schwarz Pharma, LLC; 2009.

    Google Scholar 

  30. Jackson J, Anania FA. Chlorzoxazone as a cause of acute liver failure requiring liver transplantation. Dig Dis Sci. 2007;52(12):3389–91.

    Article  PubMed  Google Scholar 

  31. Nightingale SL. Chlorzoxazone warning on hepatotoxicity is strengthened. JAMA. 1995;274:1903.

    Article  CAS  PubMed  Google Scholar 

  32. Flexeril [package insert]. Fort Washington: McNeil Consumer Healthcare, Division of McNeil-PPC, Inc.; 2010.

    Google Scholar 

  33. Addolorato G, Leggio L, Ferrulli A, Cardone S, Vonghia L, Mirijello A, Abenavoli L, D’Angelo C, Caputo F, Zambon A, Haber PS, Gasbarrini G. Effectiveness and safety of baclofen for maintenance of alcohol abstinence in alcohol-dependent patients with liver cirrhosis: randomised, double-blind controlled study. Lancet. 2007;370(9603):1915–22.

    Article  CAS  PubMed  Google Scholar 

  34. Desaphy JF, Dipalma A, De Bellis M, Costanza T, Gaudioso C, Delmas P, George Jr AL, Camerino DC. Involvement of voltage-gated sodium channel blockade in the analgesic effects of orphenadrine. Pain. 2009;142(3):225–35.

    Article  CAS  PubMed  Google Scholar 

  35. Soma [package insert]. Somerset: Meda Pharmaceuticals, Inc.; 2011.

    Google Scholar 

  36. Xanax [package insert]. New York: Pfizer, Inc.; 2011.

    Google Scholar 

  37. Midazolam [package insert]. Minneapolis: Paddock Laboratories, Inc.; 2008.

    Google Scholar 

  38. Valium [package insert]. Nutley: Roche Pharmaceuticals; 2008.

    Google Scholar 

  39. Restoril [package insert]. St. Louis: Mallinckrodt Inc.; 2006.

    Google Scholar 

  40. Trouvin JH, Farinotti R, Haberer JP, Servin F, Chauvin M, Duvaldestin P. Pharmacokinetics of midazolam in anaesthetized cirrhotic patients. Br J Anaesth. 1988;60(7):762–7.

    Article  CAS  PubMed  Google Scholar 

  41. Macgilchrist AJ, Birnie GG, Cook A, Scobie G, Murray T, Watkinson G, Brodie MJ. Pharmacokinetics and pharmacodynamics of intravenous midazolam in patients with severe alcoholic cirrhosis. Gut. 1986;27:190–5.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  42. Ultram [package insert]. Raritan: Ortho-McNeil Pharmaceutical, Inc.; 2003.

    Google Scholar 

  43. Durotram XR [package insert]. Thornleigh: iNova Pharmaceuticals; 2008.

    Google Scholar 

  44. Codeine [package insert]. Philadelphia: Lannett Company, Inc.; 2010.

    Google Scholar 

  45. Tegeder I, Lotsch J, Geisslinger G. Pharmacokinetics of opioids in liver disease. Clin Pharmacokinet. 1999;37:17–40.

    Article  CAS  PubMed  Google Scholar 

  46. Crotty B, Watson KJ, Desmond PV, Mashford ML, Wood LJ, Colman J, Dudley FJ. Hepatic extraction of morphine is impaired in cirrhosis. Eur J Clin Pharmacol. 1989;36:501–6.

    Article  CAS  PubMed  Google Scholar 

  47. Hasselstrom J, Eriksson S, Persson A, Rane A, Svensson JO, Säwe J. The metabolism and bioavailability of morphine in patients with severe liver cirrhosis. Br J Clin Pharmacol. 1990;29(3):289–97.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  48. Patwardhan RV, Johnson RF, Hoyumpa Jr A, Sheehan JJ, Desmond PV, Wilkinson GR, Branch RA, Schenker S. Normal metabolism of morphine in cirrhosis. Gastroenterology. 1981;81(6):1006–11.

    CAS  PubMed  Google Scholar 

  49. Laidlaw J, Read AE, Sherlock S. Morphine tolerance in hepatic cirrhosis. Gastroenterology. 1961;40:389–96.

    CAS  PubMed  Google Scholar 

  50. Smith HS. Opioid metabolism. Mayo Clin Proc. 2009;84(7):613–24.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  51. Hartrick CT. Tapentadol immediate-release for acute pain. Expert Rev Neurother. 2010;10(6):861–9.

    Article  CAS  PubMed  Google Scholar 

  52. Nucynta [package insert]. Raritan: Ortho-McNeil-Janssen Pharmaceuticals; 2010.

    Google Scholar 

  53. Kaiko RF. Pharmacokinetics and pharmacodynamics of controlled-release opioids. Acta Anaesthesiol Scand. 1997;41(1 Pt 2):166–74.

    Article  CAS  PubMed  Google Scholar 

  54. Tallgren M, Olkkola KT, Seppala T, Höckerstedt K, Lindgren L. Pharmacokinetics and ventilatory effects of oxycodone before and after liver transplantation. Clin Pharmacol Ther. 1997;61(6):655–61.

    Article  CAS  PubMed  Google Scholar 

  55. Oxycodone [package insert]. St. Louis: Tyco Healthcare; 2005.

    Google Scholar 

  56. Opana ER [package insert]. Chadds Ford: Endo Pharmaceuticals; 2011.

    Google Scholar 

  57. Opana (oxymorphone) [package insert]. Chadds Ford: Endo Pharmaceuticals; 2011.

    Google Scholar 

  58. Centers for Disease Control and Prevention. MMWR weekly: thrombotic thrombocytopenic purpura (TTP)—like illness associated with Opana ER intravenous abuse. 2013. http://www.cdc.gov/mmwr/preview/mmwrhtml/mm6201a1.htm

  59. Durnin C, Hind ID, Ghani SP, Yates DB, Molz KH. Pharmacokinetics of oral immediate-release hydromorphone (Dilaudid IR) in subjects with moderate hepatic impairment. Proc West Pharmacol Soc. 2001;44:83–4.

    CAS  PubMed  Google Scholar 

  60. Dilaudid [package insert]. North Chicago: Abbott Laboratories; 2007.

    Google Scholar 

  61. Eap CB, Buclin T, Baumann P. Interindividual variability of the clinical pharmacokinetics of methadone: implications for the treatment of opioid dependence. Clin Pharmacokinet. 2002;41(14):1153–93.

    Article  CAS  PubMed  Google Scholar 

  62. Novick DM, Kreek MJ, Fanizza AM, Yancovitz SR, Gelb AM, Stenger RJ. Methadone disposition in patients with chronic liver disease. Clin Pharmacol Ther. 1981;30(3):353–62.

    Article  CAS  PubMed  Google Scholar 

  63. Dolophine (methadone) [package insert]. Columbus: Roxane Laboratories, Inc., 2006.

    Google Scholar 

  64. Jacobi J, Fraser GL, Coursin DB, Riker RR, Fontaine D, Wittbrodt ET, Chalfin DB, Masica MF, Bjerke HS, Coplin WM, Crippen DW, Fuchs BD, Kelleher RM, Marik PE, Nasraway Jr SA, Murray MJ, Peruzzi WT, Lumb PD. Clinical practice guidelines for the sustained use of sedatives and analgesics in the critically ill adult. Crit Care Med. 2002;30(1):119–41.

    Article  PubMed  Google Scholar 

  65. Niscola P, Scaramucci L, Vischini G, Giovannini M, Ferrannini M, Massa P, Tatangelo P, Galletti M, Palumbo R. The use of major analgesics in patients with renal dysfunction. Curr Drug Targets. 2010;11(6):752–8.

    Article  CAS  PubMed  Google Scholar 

  66. Hervé S, Riachi G, Noblet C, Guillement N, Tanasescu S, Goria O, Thuillez C, Tranvouez JL, Ducrotte P, Lerebours E. Acute hepatitis due to buprenorphine administration. Eur J Gastroenterol Hepatol. 2004;16:1033–7.

    Article  PubMed  Google Scholar 

  67. Butrans patch [package insert]. Stamford: Purdue Pharma L.P.; 2010.

    Google Scholar 

  68. Pond SM, Tong T, Benowitz NL, Jacob P, Rigod J. Presystemic metabolism of meperidine to normeperidine in normal and cirrhotic subjects. Clin Pharmacol Ther. 1981;30(2):183–8.

    Article  CAS  PubMed  Google Scholar 

  69. Klotz U, McHorse TS, Wilkinson GR, Schenker S. The effect of cirrhosis on the disposition and elimination of meperidine in man. Clin Pharmacol Ther. 1974;16(4):667–75.

    CAS  PubMed  Google Scholar 

  70. Goodman F. Criteria for use of meperidine. Hines (IL): VHA Pharmacy Benefits Management Strategic Healthcare Group and the Medical Advisory Panel (US). 2003. www.vapbm.org

Download references

Author information

Authors and Affiliations

  1. Department of Medicine, Section of Gastroenterology, Temple University Hospital, Philadelphia, PA, USA

    Adam C. Ehrlich M.D., M.P.H.

  2. Department of Medicine, Division of Gastroenterology and Hepatology, Weill Cornell Medical College, New York, NY, USA

    Amir Soumekh M.D.

Authors
  1. Adam C. Ehrlich M.D., M.P.H.
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Amir Soumekh M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Adam C. Ehrlich M.D., M.P.H. .

Editor information

Editors and Affiliations

  1. Department of Rehabilitation Medicine, Interventional Pain Management, New York University , Langone Medical Center, New York, New York, USA

    Kimberly A. Sackheim

Rights and permissions

Reprints and permissions

Copyright information

© 2015 Springer Science+Business Media New York

About this chapter

Cite this chapter

Ehrlich, A.C., Soumekh, A. (2015). Pain Management in Patients with Hepatic Impairment. In: Sackheim, K. (eds) Pain Management and Palliative Care. Springer, New York, NY. https://doi.org/10.1007/978-1-4939-2462-2_31

Download citation

  • DOI: https://doi.org/10.1007/978-1-4939-2462-2_31

  • Publisher Name: Springer, New York, NY

  • Print ISBN: 978-1-4939-2461-5

  • Online ISBN: 978-1-4939-2462-2

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation